PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E)

被引：33
|
作者：
Campbell, A.
Reckamp, K. L.
Camidge, D. R.
Giaccone, G.
Gadgeel, S. M.
Khuri, F. R.
Engelman, J. A.
Denis, L. J.
O'Connell, J. P.
Janne, P. A.
机构：
[1] Pfizer Inc, New London, CT USA
[2] City Hope Natl Med Ctr, Duarte, CA USA
[3] Univ Colorado Denver, Aurora, CO USA
[4] NCI, Bethesda, MD 20892 USA
[5] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[6] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[7] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7596
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7596
引用
收藏
页数：1
相关论文
共 50 条
  • [21] MODULATION OF THE CYCLOOXYGENASE PATHWAY IS ASSOCIATED WITH EFFICACY IN A RANDOMIZED PHASE II TRIAL OF ERLOTINIB AND CELECOXIB OR PLACEBO IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Fishbein, Michael C.
    Gardner, Brian
    Milne, Ginder L.
    Koczywas, Marianna
    Cristea, Mihaela
    Dowell, Jonathan E.
    Wang, Hejing
    Figlin, Robert A.
    Elashoff, Robert M.
    Dubinett, Steven M.
    Reckamp, Karen L.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1094 - S1094
  • [22] Erlotinib in progressive pretreated advanced non-small cell lung cancer (NSCLC): Results of a phase II open-label trial
    Piantedosi, F., V
    Gilli, M.
    Caputo, F.
    Casale, B.
    Bianco, A.
    Dericoloso, A.
    Pontillo, A.
    Crispino, C.
    Giuliarini, G.
    Hengheller, M.
    Chianca, P.
    ANNALS OF ONCOLOGY, 2007, 18 : 26 - 26
  • [23] EFFICACY AND PATIENT (PT)-REPORTED OUTCOMES (PROS) WITH SELUMETINIB (AZD6244, ARRY-142866; SEL) + DOCETAXEL (DOC) IN KRAS-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED, PHASE II TRIAL
    Janne, P. A.
    Shaw, A. T.
    Pereira, J. R.
    Jeannin, G.
    Vansteenkiste, J. F.
    Barrios, C.
    Franke, F. A.
    Grinsted, L.
    Smith, I.
    Crino, L.
    ANNALS OF ONCOLOGY, 2012, 23 : 403 - 403
  • [24] Phase I trial of vorinostat in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations after erlotinib progression
    Reguart, N.
    Cardona, A. F.
    Isla, D.
    Cardenal, F.
    Palmero, R.
    Carrasco-Chaumel, E.
    Rolfo, C.
    Massuti, B.
    Moran, T.
    Rosell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] A phase II study of erlotinib and sorafenib in chemotherapy-naive patients with locally advanced/metastatic non-small cell lung cancer (NSCLC)
    Lind, Joline S.
    Dingemans, Anne-Marie C.
    Groen, Harry J.
    Smit, Egbert F.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S412 - S413
  • [26] A phase II study of erlotinib followed by chemotherapy on progression in an unselected population of advanced non-small cell lung cancer (NSCLC) patients.
    Horn, Leora
    Li, Chung-I
    Pao, William
    Keedy, Vicki Leigh
    Johnson, David H.
    Carbone, David P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] A phase II study of erlotinib and sorafenib in chemotherapy-naive patients with locally advanced/metastatic non-small cell lung cancer (NSCLC)
    Lind, J. S.
    Dingemans, A. C.
    Groen, H. J.
    Smit, E. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Efficacy and safety of sunitinib in a multicenter phase II trial of previously treated, advanced non-small cell lung cancer (NSCLC)
    Socinski, Mark A.
    Novello, Silvia
    Sanchez, Jose M.
    Brahmer, Julie
    Govindan, Ramaswamy
    Belani, Chandra P.
    Atkins, James N.
    Gillenwater, Heidi H.
    Palleres, C.
    Chao, Richard C.
    ANNALS OF ONCOLOGY, 2006, 17 : 218 - 218
  • [29] PROFILE 1005: PRELIMINARY PATIENT-REPORTED OUTCOMES (PROS) FROM AN ONGOING PHASE 2 STUDY OF CRIZOTINIB (PF-02341066) IN ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Blackhall, Fiona H.
    Petersen, Jennifer A.
    Wilner, Keith
    Hirsh, Vera
    Shaw, Alice T.
    Kim, Dong-Wan
    Solomon, Ben
    Janne, Pasi A.
    Reisman, Arlene L.
    Polli, Anna
    Mundayat, Rajiv
    Bottomley, Andrew
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S413 - S414
  • [30] Phase I trial of vorinostat in combination with erlotinib for advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations after erlotinib progression
    Reguart, Noemi
    Isla, Dolores
    Cardenal, Felipe
    Cardona, Andres
    Palmero, Ramon
    Moran, Teresa
    Rolfo, Christian Diego
    Nadal, Ernesto Samuel
    Massuti, Tomeu
    Montanes, Ana
    Queralt, Cristina
    Taron, Miquel
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S708 - S708
12345